Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company based in Waltham, United States. According to its website, it is committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Its pipeline of novel antibodies and combinations targets validated mechanisms with the potential to treat immune-mediated diseases, including programs SPY001 (α4β7), SPY002 (TL1A), SPY003 (IL-23), SPY120 (α4β7 + TL1A), and SPY130 (α4β7 + IL-23).

Spyre Therapeutics is a clinical-stage biotechnology company based in Waltham, United States. Its website states that it is committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. The company describes a pipeline of novel antibodies and combinations targeting validated mechanisms with the potential to treat immune-mediated diseases, listing programs SPY001 (α4β7), SPY002 (TL1A), SPY003 (IL-23), SPY120 (α4β7 + TL1A), and SPY130 (α4β7 + IL-23). It also states that its team has deep experience developing and commercializing treatments across a broad range of diseases. On December 10, 2024, the company announced grants of inducement awards.

Clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology.

• SPY001

• SPY002

• SPY003

• SPY120

• SPY130

1. 1Spyre Therapeuticsspyre.com
2. 2About | Spyre Therapeuticsspyre.com
3. 3Our Approach | Spyre Therapeuticsspyre.com
4. 4Spyre Therapeutics (United States)wikidata.org